DANIEL J. STARKS - 25 Apr 2025 Form 4 Insider Report for ABBOTT LABORATORIES (ABT)

Role
Director
Signature
/s/ Daniel J. Starks by Jessica H. Paik, Attorney-in-Fact
Issuer symbol
ABT
Transactions as of
25 Apr 2025
Transactions value $
$0
Form type
4
Filing time
29 Apr 2025, 18:22:08 UTC
Previous filing
30 Apr 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABT Common shares without par value Award $0 +1.64K +0.02% $0.00 6.73M 25 Apr 2025 Direct F1
holding ABT Common shares without par value 258 25 Apr 2025 Alynne Starks 2012 Irrevocable Trust F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABT Option (right to buy) Award $0 +4.52K $0.00 4.52K 25 Apr 2025 Common Shares 4.52K $128.40 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).
F2 Held in the Alynne Starks 2012 Irrevocable Trust. The reporting person is the sole trustee of the trust.
F3 Stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.